Title: Approaches, progress, and challenges to hepatitis C vaccine development—J. R. Bailey, et. al.
Summary: In this review, the authors discuss the challenges in the development of a fully protective vaccine against the hepatitis C virus (HCV). The obstacles include overcoming how quickly the HCV mutates or changes its genetic make-up, the limited animal models available to test an HCV protective vaccine and our limited understanding of the HCV immune response. The authors conclude that these obstacles will need to be overcome to develop an effective protective vaccine in order to effectively eliminate HCV. It is unlikely that a protective vaccine will be developed in the very near future but progress is being made.
Title: Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: a modeling study—J.A. Kwon, et. al.
Source: J Viral Hepat. 2018 Sep 29. doi: https://www.ncbi.nlm.nih.gov/pubmed/30267593 [Epub ahead of print]
Summary: This study evaluated the likelihood that Australia would reach their target goal to eliminate HCV by 2030. Using a mathematical model to simulate the epidemiology and death rates in Australia over the period 2016-2030. Australia had a very fast rate of people who initiated direct-acting antiviral therapy (DAA) in 2016 with 32,600 people treated. It should be noted that the Australian government subsidizes the cost of HCV medications.
In their analysis, Australia should meet the WHO target of HCV elimination of 10 to 15 years. However, the authors noted that due to the number of people who already had HCV disease progression prior to the beginning of the approval of DAA therapies, it would be difficult to achieve the WHO target mortality or deaths.Share This Page